Of baseball and enhancement bondage
By Pete Shanks,
San Francisco Chronicle
| 09. 26. 2005
Baseball fans around the nation have been conducting their own straw poll about human enhancement, and they don't like it. Rafael Palmeiro has practically been driven out of the game, Mark McGwire is now seen as more cartoon than hero, and Jason Giambi is treated with widespread derision.
Then there is Barry Bonds.
Bonds is -- as usual -- a lightning rod for everyone's feelings, a walking paradox who illustrates without even trying just how complex these issues are. He told reporters before his first game in Washington, D.C., that there are more serious issues than steroids, but all that did was increase the hype about his appearance. And he lived up to it.
Bonds getting booed is not unusual in a road game. But in Washington, he was booed by fans who were on their feet as he homered to the upper deck -- clapping at the same time they were jeering. Whether they were right or wrong about Bonds (who denies ever knowingly taking illegal substances), there couldn't be a more dramatic illustration of the conflicts we feel...
Related Articles
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...
By Nick Paul Taylor, Fierce Biotech | 01.09.2026
Menlo Ventures has made a $16 million bet that the “baby KJ” custom CRISPR therapy success story is repeatable. The funding has enabled CRISPR co-inventor Jennifer Doudna, Ph.D., and baby KJ scientist Fyodor Urnov, Ph.D., to launch Aurora...
By David Cox, Wired | 01.05.2026
As he addressed an audience of virologists from China, Australia, and Singapore at October’s Pandemic Research Alliance Symposium, Wei Zhao introduced an eye-catching idea.
The gene-editing technology Crispr is best known for delivering groundbreaking new therapies for rare diseases, tweaking...